M&A Deal Summary

Elanco Acquires Aratana Therapeutics

On April 26, 2019, Elanco acquired life science company Aratana Therapeutics for 245M USD

Acquisition Highlights
  • This is Elanco’s 5th transaction in the Life Science sector.
  • This is Elanco’s 5th largest (disclosed) transaction.
  • This is Elanco’s 5th transaction in the United States.
  • This is Elanco’s 1st transaction in Kansas.

M&A Deal Summary
Date 2019-04-26
Target Aratana Therapeutics
Sector Life Science
Buyer(s) Elanco
Deal Type Add-on Acquisition
Deal Value 245M USD
Advisor(s) Barclays Investment Bank (Financial)
Latham & Watkins (Legal)

Target

Aratana Therapeutics

Leawood, Kansas, United States
Aratana Therapeutics, Inc. is a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana Therapeutics, Inc. was formed in 2010 and is headquartered in Leawood, Kansas.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Elanco

Greenfield, Indiana, United States
Category Company
Founded 1954
Sector Life Science
Employees9,300
Revenue 4.4B USD (2023)
DESCRIPTION

Elanco develops and markets products and services to improve animal health and protein production in more than 75 countries. Elanco employs more than 3,000 people worldwide, with offices in more than 40 countries. Elanco was incorporated in 1954 and is based in Greenfield, Indiana.

DEAL STATS #
Overall 8 of 11
Sector (Life Science) 5 of 7
Type (Add-on Acquisition) 4 of 6
State (Kansas) 1 of 1
Country (United States) 5 of 6
Year (2019) 1 of 3
Size (of disclosed) 5 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-10-05 Boehringer Ingelheim Vetmedica - U.S. Feline Canine and Rabies Vaccines

St. Joseph, Montana, United States

Boehringer Ingelheim Vetmedica, Inc. - U.S. Feline, Canine and Rabies Vaccines is a developer of vaccines for animals. The business also inculded fully integrated manufacturing and R&D site.

Buy $885M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-08-01 Prevtec Microbia

Montreal, Quebec, Canada

Prevtec Microbia, Inc. is a Canadian biotechnology company developing and commercializing sustainable solutions as alternatives to antibiotics to improve animal health, production performance and food safety. Prevtec Microbia’s first commercial product, Coliprotec®F4, a swine E. coli vaccine, has been sold across Canada since 2007 and in the EU since 2015, and is approved in Brazil (2010) and in the US (2018).

Buy -
Mergr

Product

Company

Legal